India needs to address major problems of adverse drug reactions

29 September 2015
gateway-of-india-big

The monitoring of adverse drug reactions (ADRs) has become paramount in India, with the country eager to put in place regulatory mechanisms to curb the menace of rising ADRs, as well as continue with its emphasis on collection of data on ADRs to ensure patient safety, reports The Pharma Letter’s India correspondent.

Based on ADRs collected by the Drug Monitoring and Reporting Centers under the Pharmacovigilance Program of India, the Central Drugs Standard Control Organization (CDSCO), the apex drugs regulator in India, is also to initiate regulatory action.

"The innate tendency is to hush up such cases. As new and more drugs are being introduced into the market, like high tech pharma products, New Chemical Entities (NCEs), vaccines, new therapeutic claims of existing drugs as well as new routes of drug administrations, there are several challenges to monitoring ADRs given the large population base," said a government official.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical